Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.69 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.51 |
| ▸ | PYGM | P11217 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638220 | 1.00 | SCN9A (0.69) | SCN9ANPY1RRIPK1PYGLPYGM | |
| SCHEMBL12376364 | 1.00 | SCN9A (0.69) | SCN9ANPY1RRIPK1PYGLPYGM | |
| SCHEMBL17321249 | 0.91 | SCN9A (0.59) | SCN9ANPY1RRIPK1PYGLPYGM | |
| SCHEMBL7423602 | 0.89 | SCN9A (0.56) | SCN9APYGLPYGM | |
| SCHEMBL4799468 | 0.89 | SCN9A (0.56) | SCN9APYGLPYGM | |
| SCHEMBL4799483 | 0.89 | SCN9A (0.56) | SCN9APYGLPYGM | |
| SCHEMBL23075140 | 0.84 | SCN9A (0.52) | SCN9ANPY1RRIPK1PYGLPYGM | |
| SCHEMBL18419855 | 0.84 | SCN9A (0.55) | SCN9ANPY1RRIPK1 | |
| SCHEMBL15964614 | 0.84 | SCN9A (0.52) | SCN9ANPY1RRIPK1PYGLPYGM | |
| SCHEMBL7486160 | 0.83 | CCKBR (0.72) | SCN9ANPY1RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | SCN9A 3897/4885NPY1R 525/4885RIPK1 387/4885 |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | GABRA5, GABRA2, GABRA3 | SCN9A 709/4885NPY1R 1000/4885RIPK1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.